Hygieia Extends Series B Round to $22 Million with Participation from Strategic Investors

Livonia, Mich., May 2, 2023 – Hygieia, a digital therapeutics company for insulin therapy, is extending its Series B funding round to $22 million with a lead investment from Firstime Ventures and additional investment from two strategic partners.   Hygieia is the maker of d-Nav®, the only FDA-cleared technology to autonomously adjust insulin dose recommendations to…

Read More

Hygieia Expands to Arizona, as Endocrinology Associates, PA, Joins d-Nav® Insulin Management Clinical Partnership Program

Partnership model gives physicians better tools for insulin therapy and offers new reimbursement opportunities Livonia, Michigan, Jan. 10, 2023 — Hygieia, a provider of digital therapeutics for insulin management, has added Endocrinology Associates, PA, in Scottsdale and Chandler, AZ, as a clinical partner. This makes Hygieia’s d-Nav® autonomous insulin therapy service available to patients with type…

Read More

Hygieia adds to team, continues rapid, national expansion of its d-Nav® Insulin Management Program

Demand grows for d-Nav Technology, the first FDA-cleared app to autonomously adjust insulin doses Livonia, Michigan, Dec. 13, 2022 — Hygieia, a digital therapeutics company, has relocated and expanded its headquarters to accommodate additional staff as it continues significant growth and pursues partnerships with endocrinology practices across the United States. Hygieia’s expansion is in response to increased…

Read More

Hygieia adds clinical partners in New York and North Carolina to its
d-Nav® Insulin Management Program

Partnership model increases doctors’ ability to coordinate patients’ insulin therapy andoffers new reimbursement opportunities Livonia, Mich., Sept. 12, 2022 — Hygieia, a provider of digital therapeutics for insulin management, has added Endocrine Associates of West Village P.C. in Manhattan and Long Island City, NY, and Physicians East in Greenville, NC, as clinical partners. The partnerships are…

Read More

Hygieia adds Metro Detroit Endocrinology Center as clinical partner for its d-Nav® Insulin Management Program

New partnership expands availability of d-Nav program for underserved Livonia, Mich., August 30, 2022 — Hygieia, a provider of digital therapeutics for insulin management, has added Metro Detroit Endocrinology Center in Dearborn as a clinical partner. The partnership extends Hygieia’s d-Nav® network and makes autonomous insulin therapy service available for an underserved population. The unique…

Read More

Diabetes Technology Leader and Global Business Executive Doug Lawrence Joins Hygieia as CEO

Livonia, Michigan, Aug. 23, 2022 – Hygieia, a digital therapeutics company for insulin therapy, has appointed Doug Lawrence its chief executive officer, responsible for leading operations, development, and global growth of the company and its d-Nav® Insulin Management Program. Lawrence brings three decades of medical technology leadership to his new role at Hygieia, including significant experience…

Read More

Hygieia announces new CPT codes for autonomous insulin dose titration

Digital Therapeutics

Livonia, Mich., July 26, 2022 – Hygieia, a digital therapeutics company for insulin therapy, announces the American Medical Association (AMA) CPT Editorial Panel has approved two new Category III codes for autonomous insulin dose titration, which can be used for Hygieia’s d-Nav® Technology. d-Nav is the first FDA-cleared technology to autonomously adjust insulin dose recommendations…

Read More

Hygieia Advances its Global Business Development Activities with d-Nav® Program in Israel

Livonia, Michigan, June 23, 2022 – Hygieia, a digital therapeutics company for insulin therapy, has successfully licensed its d-Nav insulin management technology to Movement Group, a provider of health and wellness programs to integrated health delivery networks in Israel. The agreement is part of an accelerated strategy to expand its d-Nav insulin titration technology globally. d-Nav…

Read More

Hygieia Launches d-Nav® Clinical Partnership Program at AACE Annual Meeting

SAN DIEGO, Calif.–(BUSINESS WIRE)–Hygieia, a digital therapeutics company, today announced the official launch of its d-Nav Clinical Partnership Program for endocrinology practices treating patients with type 2 diabetes. The d-Nav Clinical Partnership Program is turnkey. It provides patients with access to d-Nav autonomous insulin dose technology and a clinical support team. For clinical partners, the d-Nav…

Read More

Digital insulin management company Hygieia closes on $17 million Series B investment round

Funding will enable expansion of company’s AI-driven d-Nav® technology, which automates real-time insulin dose recommendations for people with type 2 diabetes LIVONIA, Mich., December 2, 2021 – Hygieia, a digital health company for insulin management, has closed on an initial $17 million Series B investment round, led by Israeli venture capital firm Firstime Ventures, and with participation from…

Read More